Cargando…
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
Epilepsy affects ~5 out of every 10,000 children per year. Up to one-third of these children have medically refractory epilepsy, with limited to no options for improved seizure control. mTOR, a ubiquitous 289 kDa serine/threonine kinase in the phosphatidylinositol 3-kinase (PI3K)-related kinases (PI...
Autores principales: | Goldstein, Hannah E., Hauptman, Jason S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907183/ https://www.ncbi.nlm.nih.gov/pubmed/33643212 http://dx.doi.org/10.3389/fneur.2021.639319 |
Ejemplares similares
-
mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012) -
Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis
por: Zimmer, Till S., et al.
Publicado: (2020) -
Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022) -
Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015) -
Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
por: Śmiałek, Dominika, et al.
Publicado: (2023)